Enorama Pharma (Sweden) Today
| ERMA Stock | SEK 3.55 0.06 1.66% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Enorama Pharma is selling for under 3.55 as of the 29th of November 2024; that is 1.66 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.55. Enorama Pharma has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Enorama Pharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of August 2024 and ending today, the 29th of November 2024. Click here to learn more.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden. The company has 10.69 M outstanding shares. More on Enorama Pharma AB
Moving together with Enorama Stock
Moving against Enorama Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Enorama Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Enorama Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Enorama Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Enorama Pharma AB (ERMA) is traded on Stockholm Exchange in Sweden and employs 10 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 89.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enorama Pharma's market, we take the total number of its shares issued and multiply it by Enorama Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Enorama Pharma AB operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 10.69 M outstanding shares.
Enorama Pharma AB has accumulated about 2.01 M in cash with (30.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38.
Check Enorama Pharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Enorama Pharma AB is kr89.44 Million. Enorama Pharma AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 78.21 percent of Enorama Pharma AB outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Enorama Ownership Details
Enorama Pharma AB Risk Profiles
Although Enorama Pharma's alpha and beta are two of the key measurements used to evaluate Enorama Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.9 | |||
| Standard Deviation | 5.24 | |||
| Variance | 27.5 | |||
| Risk Adjusted Performance | (0.02) |
Enorama Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Enorama Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.